GlassScriptPhysician profile
Manu Pillai
NPI 1972766467
$6,309.28
in general payments reported to CMS, 2019-2025
28 companies · $787 in 2025
The $787 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $195 · 2021: $1,015 · 2022: $951 · 2023: $1,220 · 2024: $828 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,018.39 | 2019-2025 | |
| Boston Scientific Corporation | $778.36 | 2019-2025 | Bodyguardian, Mylux Patient Kit With Mobile Device, Avvigo Guidance System |
| Janssen Pharmaceuticals, INC | $512.01 | 2019-2024 | Xarelto |
| Amgen INC. | $443.16 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $387.91 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $352.85 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $295.36 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.90 | 2019-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $236.80 | 2023-2024 | Optimizer, Optimizer |
| Pfizer INC. | $206.48 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $199.81 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $190.67 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $179.64 | 2019-2024 | Cardiomems |
| Esperion Therapeutics, INC. | $177.11 | 2021-2025 | Nexletol |
| Medtronic Vascular, INC. | $158.58 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $155.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $134.59 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $104.42 | 2019-2024 | |
| Lexicon Pharmaceuticals, INC. | $85.95 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $85.13 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $84.38 | 2025 | Amvuttra |
| Kowa Pharmaceuticals America, INC. | $71.56 | 2021-2022 | |
| Novo Nordisk INC | $47.81 | 2022-2023 | Ozempic |
| Medtronic, INC. | $42.91 | 2021 | |
| Dilon Technologies, INC. | $18.73 | 2023 | Hemoblast Bellows |
| Chiesi USA, INC. | $17.46 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.90 | 2019 | |
| Scpharmaceuticals INC. | $14.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manu Pillai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.